echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 148 non-basic drugs have been eliminated from the national basic drug list or will be adjusted again

    148 non-basic drugs have been eliminated from the national basic drug list or will be adjusted again

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    1out of the catalog, the elimination of 148 non-base drugsrecently, according to the Jiangsu Provincial Pharmaceutical Alliance news, Shenzhen Central Hospital announced the 2020 phase-out of non-national basic drug varieties catalog, including a total of 148 varieties, including some clinically commonly used large varietiesin addition, in April this year, Jiangmen City, Guangdong Province, the new meeting district people's hospital issued a notice that the first quarter of this year, the use of hospital-based drugs did not meet the standardsAccording to the requirements of the local health and sanitation bureau, for two consecutive years the use of basic drugs non-conformance units will not be rated excellentIn order to prioritize the use of national-based drugs, hospitals have solicited national-based drug replacement needs from clinical departmentsthe above news, caused widespread concern in the industryOne can't help but wonder whether the hospital's move is related to the drug-based equipment policy, in accordance with theof the"Opinions on FurtherIng the Work of Supply and Stability of Shortage Drugs" issued by the General Office of the State Council on October 11, 2019, explicitly calls for the promotion of priority use of essential drugs and rational use of medicines:", "promote the priority use of essential drugs, increase the proportion of basic drug use, and adjust the national list of basic drugs in a timely manner, and gradually realize the government-run primary health care institutions, secondary levels In principle, the proportion of basic drug-equipped varieties in public hospitals and tertiary public hospitals is not less than 90%, 80% and 60%, respectively, and promote medical institutions at all levels to form a "1 plus X" ("1" for the national list of essential drugs, "X" as a non-essential drug, determined by the local authorities) drug use model, optimize and standardize the drug use structure."in addition, the National Health and Care Commission has requested local governments to carry out comprehensive pilot projects on the basic drug system, encourage urban medical groups and county medical communitytos to establish a unified drug catalogue and supply guarantee mechanism, and promote the convergence of drug use among medical institutions at the upper and lower levelsit is not difficult to see that the three-a hospital suddenly issued a notice to adjust the structure of hospital-based and non-base drugs, it is possible that the national requirements for the proportion of base drugs (the basic drugs in the grass-roots, secondary and tertiary public hospitals equipped with the number of varieties of not less than 90%, 80%, 60%, that is, the industry often said 986 policy)before the country, many provinces have issued the "Implementation of the national basic drug system comprehensive pilot program", in order to fully equipped with priority use of essential drugsAccording to Seberlan, there are no provinces to strictly implement the 986 policyfor example, Jiangsu Province has previously issued a notice requiring full yupsetting of the use of essential drugs, the formation of a basic drug-led "1 plus X" drug use model The number and amount of products equipped with the use of base medicine shall not be less than 50% in primary health care institutions, at the secondary general hospital and in the chinese hospital, and by 5-10 percentage points per year on the basis of not less than 30% for tertiary general hospitals and Chinese hospitals , however, as the policy progresses, the provinces will certainly move closer to the 986 direction required by the state In the future, the clinical status of fundamental drugs will become more and more important 2 the National Base Drug Catalog, or re-adjustment
    since June 1 this year, the People's Republic of China Basic Health care and health promotion law officially implemented, which mentions in the drug supply guarantee: "
    the state to implement the basic drug system, and in accordance with the clinical practice of drugs, drug standards changes, drug new listings, the basic drug catalog dynamic adjustment." the most recent adjustment of the base drug catalog is known to be 2018, october 25, 2018, the National Health and Health Commission issued the "Notice on the issuance of the National Essential Medicines Catalog (2018 Edition)," 685 varieties were shortlisted, the new version of the base drug catalog from November 1, 2018 on the base drug catalog, the National Health and Health Commission stressed the need to improve the directory adjustment management mechanism, regular evaluation of the catalogue, the implementation of dynamic adjustment, adjustment cycle in principle not more than 3 years; days ago, it was revealed that the relevant departments in 2020 work points clear, will be timely start the base drug catalog adjustment work When the base drug catalog will be adjusted, it has become the focus of the industry' attention in accordance with the principle of adjustment of the base drug catalog not more than 3 years, the base drug catalog this year or next year is likely to start in due course China's base medicine catalog from the earliest 307, to the following 520, now 685, the catalog is constantly expanding Under the current graded diagnosis and treatment, the expansion of the base drug catalog can meet the primary drug at the same time, covering more diseases, to meet all medical institutions medication in accordance with the requirements of the National Basic Medicines Catalog Management Measures, there are clear criteria for the transfer and transfer of the base drug catalogue the criteria for drug transfer: is to combine the disease spectrum, morbidity, disease burden, etc., to meet common diseases, chronic diseases and the burden of heavy, harmful diseases and critical and severe, public health and other basic drug needs, from the drugs already listed in China, select the appropriate quantity of essential drugs is to support the development of Chinese medicine, support the development and innovation of the pharmaceutical industry, and tilt towards Chinese medicine (including ethnic medicine) and domestic innovation medicine specification dosage form specifications, can orally doosine injection, can muscle injection does not infusion We will support the development of Chinese medicine and encourage research and development and innovation in the pharmaceutical industry The transfer process may be initiated in due course for newly approved and listed drugs with significant improvements in efficacy and reasonable prices the criteria for drug transfer: is the drug standard is replaced; is the state drug regulatory department to revoke its drug approval documents; third, adverse reactions, assessed not suitable for use as a national basic drug; fourth, according to the evaluation of drug economics, can be replaced by the risk-benefit ratio or cost-effective varieties; fifth, the National Basic Drug Work Committee should be transferred other circumstances focus on the transfer of out of the market, the serious adverse reactions are more serious, the assessment is not suitable as essential drugs, and there are risk-effective than or cost-effective replacement of drugs in principle, no medicines are added to all places, and minority areas may add a small number of ethnic medicines with the landing of the base drug policy, 986 policy will be how to advance, the future base drug catalog will be adjusted? Let's look forward to it together original title: Big Three Notice, Eliminated 148 Non-Base Drugs
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.